Skip to main content
. 2011 Jul 3;79(3):569–581. doi: 10.3797/scipharm.1104-18

Fig. 1.

Fig. 1.

A typical dose-response curve for a FACS-binding assay data set is shown. Graph in (A) shows % of binding and in (B) mean of fluorescence intensity of nimotuzumab on cell surface EGFR in two different tumor cell lines.